2023 Fiscal Year Final Research Report
Elucidation of the mechanism of hepatocarcinogenesis suppression by mitochondrial ferritin
Project/Area Number |
21K07995
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 53010:Gastroenterology-related
|
Research Institution | Kawasaki Medical School |
Principal Investigator |
HARA YUICHI 川崎医科大学, 医学部, 特任研究員 (60550952)
|
Co-Investigator(Kenkyū-buntansha) |
日野 啓輔 川崎医科大学, 医学部, 特任研究員 (80228741)
|
Project Period (FY) |
2021-04-01 – 2024-03-31
|
Keywords | mitochondria / mitophagy / HCC |
Outline of Final Research Achievements |
When the muscle mass of mice with hepatocarcinoma was evaluated based on muscle weight relative to body weight (muscle weight (mg)/body weight (g)), the average muscle weight (mg)/body weight (g) of this mouse model was 2.12, but when DFP was added to this mouse model, it significantly increased to 2.91 (p<0.05). Furthermore, when DFP was added to this mouse model in which mitophagy was specifically inhibited in the liver, muscle weight (mg)/body weight (g) decreased to 2.01, with no significant difference from control mice. Furthermore, compared with mice with hepatocarcinoma that were applied with (DMBA) and fed a high-fat diet, serum selenoprotein P in a model in which DFP was added was significantly reduced to 0.62-fold (<0.05). Furthermore, in a model in which mitophagy was specifically suppressed in the liver, serum selenoprotein P was 1.12-fold, not significantly different from untreated mice.
|
Free Research Field |
hepatology
|
Academic Significance and Societal Importance of the Research Achievements |
FTMTは以前からその存在は知られていたが、その発現機構及び機能についてはほとんど知られていない。肝発癌過程でのFTMTの発現の意義については未だ不明である。本研究でその機構が明らかになれば世界で初めての知見となる。 またFTMTの発現を促す薬剤は鉄キレート剤のみしか明らかになっていないが、鉄キレート剤はその副作用として、貧血を引き起こすことが予想される。この研究により、FTMT の発現を促す薬剤が明らかとなれば、安全で発癌抑制を期待できる薬剤が開発できることになる。FTMT発現誘導による肝発がん抑制はこれまで行われておらず、これもまた世界で初めての試みである。
|